Medication info
Diovan Film-Coated Tablets 160 mg (Valsartan)

Diovan Film-Coated Tablets 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Novartis Korea Ltd.
Appearance
Oval film-coated tablet in orange with a grayish tint
Packaging
98 tablets (14 tablets/PTP packaging x 7)
Approval status
Active

MFDS item code 200108764 · Notified 2001.10.16 · Insurance code 653600180

Summary

Main use
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the dose be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose should be increased according to the patient's tolerability, by administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is primarily used for the management of essential hypertension. It is also effective in patients with heart failure who are intolerant to ACE inhibitors, particularly those in NYHA class II to IV. Additionally, it helps reduce the mortality risk in patients with left ventricular dysfunction or systolic dysfunction after a myocardial infarction, thereby improving the patient's heart health.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the dose be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose should be increased according to the patient's tolerability, by administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Do not take this medication if you have had an allergic reaction to it or if you have severe liver or kidney disease. Elderly patients, those with high potassium levels in the blood, or patients with impaired liver function should use this medication with caution, and dosages may need to be adjusted as necessary. Due to its blood pressure-lowering effect, caution is required at the outset as sudden drops in blood pressure may cause dizziness or fainting. Patients with heart failure or those after a myocardial infarction may be affected by kidney function, thus regular monitoring is required. Blood pressure, kidney function, and serum potassium levels should be periodically checked for abnormalities during the use of this medication. Interactions may occur if taken with other antihypertensive drugs, diuretics, or potassium-sparing medications; consult a physician or pharmacist. Pregnant or breastfeeding women are advised not to use this medication, and if it must be used, breastfeeding should be discontinued. The safety and efficacy in children and adolescents have not been established, so it should be avoided in this age group. In case of overdose, severe hypotension or decreased consciousness may occur; immediate medical attention is required. Store this medication out of reach of children and do not transfer it to another container for safety. Caution is advised when driving or operating machinery as dizziness may occur.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and humidity. It is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Oval film-coated tablet in orange with a grayish tint

Package unit

98 tablets (14 tablets/PTP packaging x 7)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.